ACE Inhibitors Linked to Reduced Mortality in Idiopathic Pulmonary Fibrosis

Why It Matters

If confirmed, repurposing inexpensive, well‑tolerated ACE inhibitors could improve survival in a disease with limited therapeutic options and high mortality.

Key Takeaways

• ACE inhibitors linked to 18% lower IPF mortality
• Study analyzed 3,579 UK IPF patients
• No mortality benefit seen in COPD control group
• Findings suggest disease‑specific antifibrotic effect
• Randomized trials required to confirm causality

Pulse Analysis

Idiopathic pulmonary fibrosis remains one of the deadliest interstitial lung diseases, with median survival of three to five years despite the availability of antifibrotic agents such as nintedanib and pirfenidone. The therapeutic landscape is constrained by modest effects on long‑term mortality, prompting clinicians and researchers to look for existing drugs that could modify disease progression. ACE inhibitors, long‑standing treatments for hypertension and heart failure, have emerged as candidates because the renin‑angiotensin system is implicated in fibrotic signaling pathways. Such repurposing strategies also reduce development timelines compared with novel drug discovery.

In a recent analysis published in Chest, researchers leveraged the UK Clinical Practice Research Datalink to follow 3,579 patients diagnosed with IPF between 2002 and 2019. After propensity matching with an equal COPD cohort and adjusting for age, sex, smoking, comorbidities and socioeconomic status, ACE‑inhibitor use was associated with a hazard ratio of 0.82, translating into an 18 % relative reduction in all‑cause mortality. Importantly, the same association was absent in the COPD control group, reinforcing the hypothesis that the survival benefit is disease‑specific rather than a generic cardiovascular effect. Sensitivity analyses upheld the association, suggesting robustness against residual confounding.

If subsequent randomized trials confirm causality, ACE inhibitors could become a low‑cost, widely accessible adjunct to existing antifibrotics, potentially extending survival without adding significant adverse effects. Their established safety profile would simplify regulatory pathways and allow rapid integration into clinical practice, especially for patients already receiving cardiovascular therapy. Moreover, the findings revive interest in targeting the renin‑angiotensin axis for fibrotic lung disease, opening avenues for novel combination regimens and biomarker‑driven patient selection. Health‑economic models would likely show favorable cost‑effectiveness given the drugs' generic status.